Isa Iber VD

Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1/2
Enrollment
88 patients (estimated)
Sponsors
Dana-Farber Cancer Institute
Tags
Monoclonal Antibody, CD38
Trial Type
Treatment
Last Update
SparkCures ID
2258
NCT Identifier
NCT07601100

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.